All News

September 21, 2020

Atara Biotherapeutics’ allogeneic EBV-targeted T-cell therapy, ATA188, is well-tolerated in phase 1, with a dose identified for the randomized placebo-controlled portion of the study.

September 21, 2020

Future research may help better characterize whether fatigue interventions aimed at one patient population may be effective in the other.

September 21, 2020

In honor of World Alzheimer’s Day, NeurologyLive is sharing some of the latest clinical developments and thoughts from leaders in the field.

September 21, 2020

Experts review the challenges of managing OFF episodes in Parkinson's disease and the current treatment options to optimize therapy.

September 21, 2020

David Dodick, MD, reviews changes to the treatment landscape for acute migraine.

September 21, 2020

The neurologist at Mayo Clinic shared his thoughts on the need to raise awareness of Alzheimer disease on World Alzheimer’s Day.

September 20, 2020

Marinus Pharmaceuticals’ positive allosteric GABAA receptor modulator ganaxolone was associated with significant median reductions in 28-day major motor seizure frequency compared to placebo.

September 19, 2020

A pair of datasets from the phase 3b CASTING study of ocrelizumab (Ocrevus; Genentech) suggest that patients treated with the agent experienced high rates of no evidence of disease activity status regardless of prior DMT exposure.

September 19, 2020

Neurology News Network for the week ending September 19, 2020.

September 18, 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 18, 2020.